Essentials for Diagnosing and Treating HER2 Low/Ultralow mBC

CE / CME

Shining a Light on HER2-Low and HER2-Ultralow Metastatic Breast Cancer: A Pathologist’s Guide to Bridging the Diagnostic Gaps

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABPath MOC: maximum of 1.00 Lifelong Learning point

Released: April 25, 2025

Expiration: October 24, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following patients with unresectable or metastatic breast cancer would qualify for treatment with T-DXd?

2.

Which of the following is recommended to optimally assess HER2 status to identify patients with MBC who may benefit from HER2-targeted therapy?

3.

How confident are you in identifying HER2-low/ultralow BC?